LONG ISLAND, N.Y., Jan. 11 /PRNewswire/ — Metropolitan Area women suffering from the painful, embarrassing side effects of uterine fibroids now have local access to a revolutionary non-invasive outpatient procedure that combines magnetic resonance imaging and focused ultrasound to destroy these tumors. ExAblate of Long Island, the first Metropolitan Area facility to offer this incisionless procedure with the ExAblate 2000 system, is now open at 900 Northern Boulevard in Great Neck.
“The ExAblate technology combines magnetic resonance imaging and focused ultrasound, which enables us to not only see the fibroid and surrounding organs in 3D, but to destroy the targeted tumors inside the body without the need for traditional surgical incisions. On average, patients return to normal activities in one to two days. Other surgical treatments for fibroids are invasive and can require several days of hospital stay and up to six weeks of recovery time,” said Ronda Snowden M.D., partnering physician for ExAblate of Metro New York.
The ExAblate treatment offers women with symptomatic uterine fibroids the only non-invasive alternative to surgical treatment options such as hysterectomy, myomectomy, and uterine artery embolization (UAE). Hysterectomy, the full removal of the uterus can lead to complications associated with major surgery and will send the patient into early menopause. The procedure requires two to five days of hospitalization and six to eight weeks of recovery. Myomectomy, the surgical removal of he fibroid, and UAE both require hospitalization and lengthy recovery time. With ExAblate, the patient goes home the same day of the procedure and can return to her normal activities within two days.
Over 2,500 patients worldwide have already benefited from The ExAblate treatment which is the only U.S. Food and Drug Administration (FDA) — approved system to use the breakthrough MR-guided Focused Ultrasound (MRgFUS) technology that combines MRI — to visualize tissues in the body, plan the treatment and monitor, in real time, treatment outcome – and high intensity focused ultrasound to thermally ablate tissue. MR thermal feedback, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. ExAblate received FDA approval for the treatment of symptomatic uterine fibroids in October 2004.
ExAblate of Metro New York is a joint venture between local physicians and Deployed Medical Solutions Inc., a Houston, Texas based company dedicated to providing patients and gynecologists access to this revolutionary new technology. Deployed Medical Solutions owns and operates six facilities across the country.
“We are pleased that we will be able to offer our gynecologists and the women of New York, New Jersey, and Connecticut, access to this new, non- invasive treatment for a condition that has previously only been treated with invasive surgery,” said Charles Cohen, president and chief executive officer of Deployed Medical Solutions, Inc.
For more information on the ExAblate procedure please visit us on the web at http://www.exablate.net/ and http://www.exablateoflongisland.com/ or call toll free: 877-ExAblate (877-392-2523)
About Uterine Fibroids
Uterine fibroids are benign growths in the uterus that affect approximately 13 million women of child bearing age in the U.S. and can cause heavy bleeding that leads to anemia, bloating, abdominal pain and other symptoms. Each year approximately 200,000 women have hysterectomies to treat uterine fibroids. Unlike hysterectomy, myomectomy and UAE, ExAblate is completely non-invasive, using MR guided focused ultrasound to thermally ablate (destroy) growths in the uterus. For women this means no hospital stay and only 1-2 days of recovery as opposed to one week (UAE); two weeks (myomectomy); or six weeks (hysterectomy) usually associated with treatment of this condition.
About ExAblate of Metro New York
ExAblate of Metro New York provides access to the ExAblate technology to gynecologists who understand their patients’ need for a non-invasive yet effective option for treating uterine fibroids. ExAblate of Metro New York will be the first and only entity in the Metropolitan Area that provides this innovative procedure. ExAblate of Metro New York is a dedicated provider of the ExAblate procedure using MR guided Focused Ultrasound Surgery that significantly improves the patient’s quality of life.
Deployed Medical Solutions Inc.
Web site: http://www.exablate.net/http://www.exablateoflongisland.com/